|
|
|
|
|
|
by ilya_m
748 days ago
|
|
|
It is: > In the phase 3 trial, 296 patients with advanced forms of non-small cell lung cancer were randomly assigned to receive either lorlatinib (149 patients) or crizotinib (147 patients, of whom 142 ultimately received treatment). |
|
|